Seeking Alpha
26 Sept 2026, 07:09 UTC · 1h ago
Verdict
Source says Buy. We score PFE +0.80 across three claims.
Score confirms the headline.
Buy
Rating stated in the headline
+0.80strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Management guides to high single-digit revenue CAGR from 2028 to 2033, implying 2033 revenue of $21–26B above consensus estimates.
Priced inanalysis of existing management guidance
So whatIf realized, this gap suggests the current P/E multiple is severely undervalued relative to 2033 terminal value.
More positive than 93% of claims this week
The Vyndamax settlement secures $2–3B in annual revenue through 2031.
Continue reading
5 related stories
More positive than 88% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inanalysis of existing settlement terms
So whatThis revenue floor offsets the anticipated post-2026 revenue decline modeled by consensus.
More positive than 79% of claims this week
Pfizer's $13B product base is currently compounding at a rate of 20% plus.
Priced inanalysis of current product performance
So whatMaintaining this growth rate would add ~$2.6B to the top line in a single year.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company is rated as a buy due to strong product growth and revenue projections that exceed consensus estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
PFE hasn't traded since this ran. Last close $28.67 (Sep 25); the reaction starts at the next open.
PFE chart →
